You are here: Industry Insights > ALL

News List

InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China PharmaSources
March 10, 2023
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 inhibitor ICP-248 in China.
IASO Biotheraputics' CT120 Granted Orphan Drug Designation by the U.S. FDA prnasia
November 26, 2021
IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative medicine announced on Oct 26, 2021 that the Office of Orphan Products Development...
Jazz Pharma’s blood cancer therapy Rylaze wins US approval pharmatimes
July 02, 2021
The US Food and Drug Administration has approved Dublin-based Jazz Pharmaceutical’s Rylaze for the treatment of two blood cancers – acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).
CAR T therapy achieves high remission rate in acute lymphoblastic leukaemia trial europeanpharmaceuticalreview
June 18, 2021
Trial data shows 71 percent of adult B cell acute lymphoblastic leukaemia patients receiving Tecartus® autologous anti-CD19-transduced CD3+ cell infusion achieved complete remission.
Novartis receives approval for Kymriah (tisagenlecleucel) by Health Sciences Authority as Singapore's first commercially approved CAR-T therapy prnasia
March 11, 2021
Novartis announced that the Health Sciences Authority (HSA) has approved Kymriah (tisagenlecleucel) as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue and gene therapy products (CTGTP) ...
Innovations in CAR-T therapies in APAC will make market more competitive, report highlights europeanpharmaceuticalreview
March 05, 2020
Research has shown that the CAR-T therapies in development in Asia-Pacific will make the worldwide market more competitive and drive down prices.
Overweight, Obesity May Up Early Mortality Risk in Pediatric ALL drugs
August 06, 2019
For Mexican children with acute lymphoblastic leukemia (ALL), overweight and obesity are predictors of early mortality...
Amgen’s Blincyto gets expanded indication for B-cell ALL in Europe pharmaceutical-technology
January 24, 2019
The European Commission (EC) has granted approval for the use of Amgen’s Blincyto as a monotherapy to treat adults with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL)....
FDA Approves Asparlas (calaspargase pegol-mknl) for Acute Lymphoblastic Leukemia (ALL) drugs
December 21, 2018
The Food and Drug Administration approved calaspargase pegol-mknl (ASPARLAS, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for.....
Predictions of early responses in paediatric acute lymphoblastic leukaemia europeanpharmaceuticalreview
December 17, 2018
Researchers have identified markers of pediatric acute lymphoblastic leukaemia to predict early relapses by testing levels of nucleotide excision repair…

Previous page 1 2 Next page